What is Integrity Laboratories?
Integrity Laboratories operates at the intersection of biotechnology and clinical diagnostics, specializing in antimicrobial stewardship. By leveraging high-complexity diagnostic solutions, the company addresses critical gaps in infectious disease detection. Their core offerings, including the RespiPlex AIO test and the intercept PCR molecular diagnostics platform, provide healthcare providers with the rapid, actionable data necessary for targeted therapeutic interventions. This technological infrastructure not only enhances patient outcomes but also serves as a vital tool for healthcare systems aiming to optimize costs through precision medicine and advanced analytics.
How much funding has Integrity Laboratories raised?
Integrity Laboratories has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Integrity Laboratories
PPP
Public-Private Partnership
What's next for Integrity Laboratories?
With this late-stage financing, Integrity Laboratories is well-positioned to scale its diagnostic footprint across broader healthcare networks. The strategic deployment of these funds will likely focus on expanding the reach of their molecular diagnostic platforms and deepening their integration with existing insurance and hospital systems. As the demand for rapid, precise infectious disease diagnostics remains a priority in modern medicine, the company is poised to leverage its current momentum to drive further innovation in antimicrobial stewardship, potentially setting new standards for clinical diagnostic accuracy and operational efficiency in the coming fiscal periods.
See full Integrity Laboratories company page
